Cadila Healthcare Limited has informed the Exchange regarding a press release dated December 13, 2021, titled "Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia".
Press Release Dec 13 2021
Filed with NSE · · 3 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 10 2021
- Press Release Nov 23 2021
- Press Release Nov 20 2021
- Press Release Nov 18 2021
- Press Release Nov 12 2021
Later from Zydus Lifesciences
- Press Release Dec 16 2021
- Press Release Dec 22 2021
- Press Release Dec 31 2021
- Press Release Jan 20 2022
- Press Release Feb 02 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences